The biopharmaceutical company is providing more than $21m for an investment partnership with Jinsheng Capital with a projected close of approximately $87m.

University of Oxford-founded OMass Therapeutics has extended its series A round to progress a pipeline targeting immunological and genetic disorders.

Ackermans & van Haaren fund Sofinim returned for a $20.6m round that will fund the cancer-analysis software provider's expansion and product development.

Debiopharm Innovation Fund and Philips Health Technology Ventures both contributed to the latest round for the cancer care software producer.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Hebei Port, Pharscin Pharma, Xiamen Fig, Fujian Sunner and Sichuan Daily Press have all contributed to a $229m biomedicine fund raised by the private equity vehicle.

Stanford-StartX Fund contributed to a $12m round for catheter monitor developer CloudCath, whose clinical advisory chairman hails from Stanford University.

ResMed joined another medical device producer, Cochlear, in a $27.2m round that will help Nyxoah get regulatory clearance for its sleep apnoea system in the US.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds

The precision cancer therapy developer, based on research from several universities, floated at the top of an upsized range and saw its price continue to rise post-IPO.